P. Ward

发表

3-Phosphoinositide-Dependent Protein Kinase-1/Akt Signaling Represents a Major Cyclooxygenase-2-Independent Target for Celecoxib in Prostate Cancer Cells

S. Kulp, Y. Yang, Chin-Chun Hung, 2004, Cancer Research.

Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3

P. Ward, J. L. Smith, D. Crawford, 2001, Journal of gastroenterology and hepatology.

Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis.

P. Ward, S. Goldwurm, L. Powell, 1998, Gastroenterology.

Alcohol dehydrogenase polymorphisms and predisposition to alcoholic cirrhosis

Ting-kai Li, B. Balkau, P. Ward, 1993, Hepatology.

Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer

T. Julian, C. Geyer, D. Wickerham, 2015 .

Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose‐finding Study

J. Hainsworth, P. Ward, L. Hart, 2018, Clinical breast cancer.

Population distribution of alcohol dehydrogenase class I in France: comparison with other populations, and distribution with respect to gender and age. The French Group for Research on Alcohol and Liver.

P. Ward, C. Coutelle, B. Fleury, 1998, Alcohol and alcoholism.

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2‐negative Breast Cancer

J. Hainsworth, P. Ward, D. Yardley, 2019, Clinical breast cancer.

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

T. Julian, C. Geyer, P. Ward, 2021, Breast Cancer Research and Treatment.

Modeling growth factor activity during proinflammatory stress: methodological considerations in assessing cytokine modulation of IGF binding proteins released by cultured bovine kidney epithelial cells.

P. Ward, S. Kahl, T. Elsasser, 2007, Domestic animal endocrinology.

Abstract P3-12-01: Impact of treatment on quality of life (QOL) and menstrual history (MH) in the NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide

E. Perez, N. Wolmark, P. Ward, 2015 .

A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC

T. Burns, P. Ward, D. Camidge, 2021 .

Development of Steroidal Inhibitors of Cytochrome P450-Dependent Androgen and Estrogen Biosynthesis /

P. Ward, 1996 .

Isolation of plasma-membrane components from cultured human pancreatic cancer cells by immuno-affinity chromatography of anti-beta 2M sepharose 6MB.

P. Ward, J. Hermon-Taylor, S. Påhlman, 1979, British Journal of Cancer.

Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.

J. Hainsworth, P. Ward, D. Yardley, 2016, Clinical breast cancer.

Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.

R. Beart, N. Wolmark, D. Moore, 2015, Journal of the National Cancer Institute.

A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.

Suzanne F. Jones, J. Hainsworth, P. Ward, 2019, The oncologist.

Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.

N. Petrelli, R. Beart, N. Wolmark, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

E. Perez, C. Geyer, P. Ward, 2022, Breast Cancer Research and Treatment.

245PDDuration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2– ABC

P. Ward, F. Esteva, M. Campone, 2017 .

Role of alcohol dehydrogenase 3 and cytochrome P‐4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract

P. Dayer, P. Ward, S. Benhamou, 2000, International journal of cancer.

Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms

P. Couzigou, P. Ward, C. Coutelle, 1997, Human Genetics.

Re: Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers.

P. Dayer, P. Ward, S. Benhamou, 1998, Journal of the National Cancer Institute.

Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.

P. Ward, L. Molinero, L. Emens, 2021, Clinical breast cancer.

Abstract PD1-05: Atezolizumab in combination with trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive breast cancer and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer: Safety and biomarker outcomes from a multi-cohort Phase Ib st

P. Ward, L. Molinero, L. Emens, 2020 .

Closing the Testing Gap: Standardization of Comprehensive Biomarker Testing for Metastatic Non–Small-Cell Lung Cancer in a Large Community Oncology Practice

P. Ward, D. Waterhouse, M. Neubauer, 2023, JCO oncology practice.

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

P. Ward, F. Esteva, M. Campone, 2018, Breast Cancer Research and Treatment.

Biochemistry and pharmacology of 7α-substituted androstenediones as aromatase inhibitors

P. Ward, N. E. Gilbert, R. Brueggemeier, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer.

T. Burns, P. Ward, D. Camidge, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).

L. Livi, E. Felip, P. Ward, 2023, Journal of Clinical Oncology.

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Simak Ali, P. Ward, J. O’Shaughnessy, 2023, Nature communications.